Shank3 deletion in PV neurons is associated with abnormal behaviors and neuronal functions that are rescued by increasing GABAergic signaling.
Jessica Pagano, Silvia Landi, Alessia Stefanoni and 9 others
PMID 37528484WHAT IT FOUND
Deleting Shank3 in parvalbumin neurons caused repetitive grooming and memory issues in mice.
Ganaxolone, which boosts GABA signaling, reversed these deficits. This suggests GABAergic modulation may help Shank3-related symptoms, but human trials are needed.
Key findings
01Selective deletion of Shank3 in parvalbumin neurons caused repetitive behaviors, memory impairments, and motor problems in mice.
02Treatment with ganaxolone, a GABA-A receptor positive allosteric modulator, rescued repetitive behavior, memory deficits, and motor coordination issues in the mutant mice.
03The mutant mice exhibited cortical hyperexcitability, which was linked to the behavioral deficits.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was conducted entirely in mice, so findings may not translate to humans. The behavioral deficits observed in the PV-specific deletion model did not include social or communication impairments, which are key features of Phelan-McDermid syndrome in humans. The mechanisms linking Shank3 deletion to specific behaviors remain unclear. Ganaxolone's effects were tested acutely; long-term safety and efficacy are unknown.
Declared interests
The paper does not report specific conflicts of interest or funding sources in the provided text.
The easy way to misread this
Do not assume ganaxolone or other GABAergic drugs are currently available or proven effective for treating human symptoms of Phelan-McDermid syndrome. This is preclinical animal research; clinical trials are necessary to determine safety and efficacy in patients.